Clinical trial
11ß-HSD1 and Metabolic Syndrome
NCT00370305 · Charite University, Berlin, Germany, Other · Completed
Key facts
| NCT number | NCT00370305 |
|---|---|
| Title | 11ß-HSD1 and Metabolic Syndrome |
| Official title | The Pathogenic Role of 11ß-hydroxysteroid Dehydrogenase in the Metabolic Syndrome - the Effect of Rosiglitazone |
| Lead sponsor | Charite University, Berlin, Germany, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metabolic Syndrome, Impaired Glucose Tolerance |
| Intervention type | Drug |
| Interventions | rosiglitazone |
| Enrollment | 24 |
| Start date | May 1, 2004 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Aug 31, 2006 |
| Last update posted | Jan 16, 2018 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: